Anti-CTLA-4 (Ipilimumab; Yervoy) [171,172] and Anti-PD-1 (Nivolumab; Option and Pembrolizumab; Keytruda) monoclonal antibodies have been approved by the US FDA for melanoma (a type of skin cancer) treatment [172,173,174] and are been currently tested in various tumor types [175,176]. Here, CTLA4 is linked to neoplasm.